15,048 Stryker Corporation $SYK Shares Acquired by Eurizon Capital SGR S.p.A.

Eurizon Capital SGR S.p.A. raised its holdings in shares of Stryker Corporation (NYSE:SYK) by 16.3% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 107,386 shares of the medical technology company’s stock after purchasing an additional 15,048 shares during the quarter. Eurizon Capital SGR S.p.A.’s holdings in Stryker were worth $29,587,000 as of its most recent SEC filing.

Other institutional investors have also recently bought and sold shares of the company. Gables Capital Management Inc. acquired a new position in shares of Stryker during the second quarter valued at about $25,000. Kilter Group LLC acquired a new stake in shares of Stryker in the 2nd quarter worth about $25,000. Highland Investment Advisors LLC bought a new position in Stryker in the 2nd quarter valued at about $25,000. Cornerstone Financial Management LLC boosted its stake in Stryker by 66.0% during the 2nd quarter. Cornerstone Financial Management LLC now owns 78 shares of the medical technology company’s stock valued at $25,000 after purchasing an additional 31 shares during the last quarter. Finally, Compass Financial Management LLC acquired a new position in Stryker during the 2nd quarter valued at about $27,000. Institutional investors and hedge funds own 77.09% of the company’s stock.

Stryker Stock Down 1.1%

SYK opened at $309.05 on Friday. Stryker Corporation has a twelve month low of $267.00 and a twelve month high of $389.33. The company’s 50-day moving average price is $292.30 and its two-hundred day moving average price is $322.60. The stock has a market cap of $117.65 billion, a price-to-earnings ratio of 32.91, a PEG ratio of 2.14 and a beta of 0.78. The company has a quick ratio of 1.30, a current ratio of 2.18 and a debt-to-equity ratio of 0.60.

Stryker (NYSE:SYK) last issued its earnings results on Thursday, October 29th. The medical technology company reported $3.52 earnings per share (EPS) for the quarter, missing the consensus estimate of $3.55 by ($0.03). Stryker had a net margin of 13.78% and a return on equity of 23.74%. The firm had revenue of $6.52 billion during the quarter, compared to the consensus estimate of $6.62 billion. During the same quarter in the previous year, the firm earned $3.19 earnings per share. The business’s quarterly revenue was up 7.6% compared to the same quarter last year. As a group, equities analysts expect that Stryker Corporation will post 14.85 earnings per share for the current year.

Insider Activity at Stryker

In other news, insider Debra King sold 826 shares of the business’s stock in a transaction that occurred on Tuesday, August 18th. The shares were sold at an average price of $336.30, for a total value of $277,783.80. Following the sale, the insider owned 6,210 shares of the company’s stock, valued at $2,088,423. The trade was a 11.74% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Ronda E. Stryker sold 550,000 shares of the company’s stock in a transaction that occurred on Friday, November 6th. The shares were sold at an average price of $325.32, for a total transaction of $178,926,000.00. Following the sale, the director owned 1,701,375 shares in the company, valued at $553,491,315. The trade was a 24.43% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last three months, insiders have sold 901,267 shares of company stock worth $297,123,701. Company insiders own 4.60% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on SYK. UBS Group decreased their price objective on Stryker from $400.00 to $382.00 and set a “buy” rating for the company in a report on Monday, August 3rd. BTIG Research cut their target price on Stryker from $316.00 to $304.00 and set a “buy” rating on the stock in a research report on Friday, October 30th. Johnson Rice downgraded Stryker to a “hold” rating in a report on Friday, October 30th. Raymond James Financial reissued an “outperform” rating and issued a $323.00 price target (down from $370.00) on shares of Stryker in a research report on Friday, October 30th. Finally, Needham & Company LLC dropped their price objective on Stryker from $418.00 to $359.00 and set a “buy” rating on the stock in a research note on Friday, October 30th. Twenty-one analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the company. According to MarketBeat.com, Stryker presently has an average rating of “Moderate Buy” and a consensus target price of $342.19.

Stryker Company Profile

Stryker is a medical technology company that develops and sells products and services for healthcare providers. Its offerings include orthopedic implants and surgical equipment, neurotechnology and spine products, and medical and surgical equipment used in hospitals and other care settings. The company’s products also include patient-handling and emergency medical equipment, as well as instruments and technologies that support surgical procedures. Stryker serves healthcare customers in the United States and internationally.